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Abstract
Loss-of-function mutations of cyclic-AMP response element binding protein, binding protein 
(CREBBP) are prevalent in lymphoid malignancies. However, the tumour suppressor functions of 
CREBBP remain unclear. We demonstrate that loss of Crebbp in murine haematopoietic stem and 
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progenitor cells (HSPC) leads to increased development of B-cell lymphomas. This is preceded by 
accumulation of hyperproliferative lymphoid progenitors with a defective DNA damage response 
(DDR) due to a failure to acetylate p53. We identify a pre-malignant lymphoma stem cell 
population with decreased H3K27ac, which undergoes transcriptional and genetic evolution due to 
the altered DDR, resulting in lymphomagenesis. Importantly, when Crebbp is lost later in 
lymphopoiesis, cellular abnormalities are lost and tumour generation attenuated. We also 
document that CREBBP mutations may occur in HSPC from patients with CREBBP-mutated 
lymphoma. These data suggest that earlier loss of Crebbp is advantageous for lymphoid-
transformation and inform the cellular origins and subsequent evolution of lymphoid 
malignancies.
Introduction
The Cyclic-AMP response element binding protein, binding protein CREBBP (also known 
as CBP and KAT3A) is a general transcriptional co-activator. CREBBP and its paralog 
EP300 (also known as p300 and KAT3B) control processes during development and 
homeostasis through binding to multiple protein partners and acetylating lysine residues of 
histone (including H3K27Ac, H3K18Ac and H3K56Ac) and non-histone substrates1. 
Germline loss-of-function mutations of CREBBP in the Rubinstein-Taybii cancer 
predisposition syndrome suggested a tumour suppressor role for CREBBP2, and early 
mouse models subsequently confirmed this3. More recently, somatic mutations, 
predominantly hemizygous and affecting the acetyltransferase domain, or deletions of 
CREBBP, have been described across a large number of sporadic tumours including myeloid 
haematological malignancies)4,5. However, CREBBP mutations are particularly frequent in 
both primitive and mature lymphoid malignancies, occurring in around 20% of relapsed B-
cell Acute Lymphoblastic Leukaemias (ALL)6, 40% of diffuse large B-cell lymphomas 
(DLBCL)7, 60% of follicular lymphomas (FL)8 and also in T-ALL9 and cutaneous T-cell 
lymphomas10. The mutations may occur throughout disease development, with variant 
allele frequency analysis demonstrating their very early acquisition in FL but longitudinal 
studies documenting their enrichment in relapsed ALL6 11,12. Despite this, the full extent 
of CREBBPs function as a tumour suppressor and the reason for its predilection for the 
lymphoid lineage remain unanswered questions.
Many cancers are dependent upon a population of stem or initiating cells for their continued 
growth and relapse, identifying a critical target population for therapeutic eradication12. 
However, for mature lymphoproliferative disorders (LPD), such as lymphomas, although 
malignant stem cell populations are predicted, direct evidence for their existence is 
controversial13 and if present, their identity and provenance are mysterious. Moreover, the 
molecular and cellular perturbations that direct the evolution of this transformed cell towards 
a fully blown lymphoma remain entirely unknown. The target cell for transformation in 
mature lymphoid malignancies had previously been presumed to be a cell with inherent self-
renewal and capable of antigenic memory14,15. However, the demonstration of clonal 
human lymphopoietic reconstitution in murine xenotransplant recipients of haematopoietic 
stem and progenitor cell (HSPC) populations from chronic lymphocytic leukaemia (CLL) 
patients16 and the existence of “driver” mutations, such as BRAF and SF3B1 mutations, in 
Horton et al. Page 2
Nat Cell Biol. Author manuscript; available in PMC 2018 February 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
HSPC from hairy cell leukaemia (HCL) and CLL patients17 18 has challenged this 
hypothesis19.
In this study, we investigate the tumour suppressor functions of Crebbp in isolation and 
describe murine models with conditional inactivation of Crebbp at different stages of 
lymphopoiesis. Mice with early loss of Crebbp within the HSPC compartment demonstrate 
alterations of transcription, epigenetic regulation and DNA damage response (DDR) and an 
increased frequency of an aggressive LPD/lymphoma. This lymphoma is preceded by a 
distinct pre-malignant phase, allowing the interrogation of transcriptional, epigenetic and 
genetic events occurring during lymphoma evolution. In contrast, loss of Crebbp in 
committed lymphoid cells significantly abrogates the cellular phenotype and markedly 
reduces tumour development. Finally, we demonstrate the relevance of this for human 
disease, detecting a CREBBP mutation in the HSPC compartment of a patient whose 
lymphoma carried the same mutation. Taken together, these data have profound implications 
for the potential cellular origins and subsequent evolution of lymphoid malignancies.
Results
Crebbp loss predisposes to an aggressive B-cell malignancy
Initially, we aged a cohort of mice where excision of Crebbp occurs within the HSPC 
compartment, following pIpC-mediated Mx1-Cre recombinase expression (hereafter Mx-
Crebbp-/- mice)20,21. Compared with wild-type littermate controls, Mx-Crebbp-/- mice 
displayed a significantly shorter survival (Figure 1a, p<0.0001), with the incidence of 
haematological malignancies, particularly B-cell malignancies, more than doubled 
(accounting for 29% of all deaths, Figure 1b and Table S1-3). These mice developed a long-
latency aggressive LPD/Lymphoma with predominantly blood and splenic involvement 
(Figure 1c-d), although ~10% also demonstrated lymphadenopathy. Tumour analysis 
revealed low and high-grade morphology (Figure 1d), a mature surface phenotype (B220+, 
CD19+, sIgM+), with aberrant expression of the B1-like markers Mac1 and CD5 (Figure 1e), 
and reflected aspects of human lymphoid malignancies associated with high frequencies of 
CREBBP mutations. The LPD also efficiently transferred disease to secondary recipients 
(Figures 1f)
Crebbp loss alters transcriptional and epigenetic regulation to change lymphoid 
progenitor function
We have previously shown that loss of Crebbp in HSPC leads to stem and progenitor 
alterations, with a significant reduction of mature B and T-cells apparent at later time-
points21,22. At earlier time-points (8-10 weeks post-pIpC), Mx-Crebbp-/- mice 
demonstrated a significant increase in lineage negative cells (Lin-) within bone marrow 
(BM) and peripheral blood (PB), with an increase of IL-7receptor α positive (IL-7Ra+) 
progenitors in BM when compared with wild type (WT) controls (Figure 2a-b). Despite this, 
the frequency of common lymphoid progenitors (CLPs) and all downstream B cell 
compartments including mature B and T cell populations were not altered at this time point 
(Figure S1a-d). This IL-7Ra+ compartment demonstrated lymphoid and limited myeloid 
potential in methylcellulose assays (Figures 2c and S1e). Crebbp-/- IL-7Ra+ cells showed 
Horton et al. Page 3
Nat Cell Biol. Author manuscript; available in PMC 2018 February 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
increased proliferation and clonogenic potential in lymphoid colony assays and enhanced 
self-renewal when compared with WT controls (Figures 2c and S1e). RNA-Seq analysis of 
this early IL-7Ra+ progenitor population revealed subtle differential gene expression 
between Mx-Crebbp-/- and WT mice (Table S4), with 97 genes including oncogenes Pbx3, 
Ets2, Yes1 and Yap1 upregulated and 101 genes including the lymphoid transcription factors 
and tumour suppressor genes Tcf7 and Bcl11b, and the Notch inhibitor Dtx123 
downregulated (Figure 2d). Geneset enrichment analysis (GSEA) demonstrated significant 
enrichment for genes differentially regulated in CREBBP mutant lymphomas24 and also 
core ES cell, HSC and proliferation signatures (Figures 2e and S1f). Genomewide H3K27ac 
binding by ChIP-Seq revealed a larger number of differentially bound peaks; 416 peaks were 
downregulated from WT to Crebbp-/- progenitors, although only a small number of these 
overlapped with the downregulated genes (9/101, 10%) at this early time point (Figure 2f-g). 
These data link Crebbp loss in the HSPC compartment with altered transcriptional and 
epigenetic regulation, disordered lymphoid differentiation and expansion of a 
hyperproliferative progenitor population with in vitro self-renewal potential.
Crebbp -/- progenitors acquire in vivo self-renewal and premalignant potential
Serial analysis of PB in Mx-Crebbp-/- mice identified a population of aberrant lymphocytes, 
with a B220+/Mac1Int phenotype, similar to that observed in the overt LPD. This population 
was detected in the blood of every animal that succumbed to the disease, appearing as early 
as 10 weeks after pIpC administration and was often detectable many months prior to the 
development of disease (Figure 3a-b). We hypothesised that this population was a pre-
malignant ancestral population from which the overt Lymphoma evolved and tested its stem 
cell properties in vivo. “Pre-malignant” (PM) Mx-Crebbp-/- mice were identified by the 
presence of a B220+ Mac1Int population and a normal white cell count (WCC) on PB 
testing, absence of clinical symptoms and a normal spleen weight upon necropsy. The LSK 
population was isolated from the BM and the B220+/Mac1Int putative PM stem cell 
population was isolated from the spleen and were transplanted independently across a 
congenic background (Figure 3c). Remarkably, highly efficient reconstitution (≥ 25% of PB) 
by the B220+/Mac1Int population was demonstrated in every recipient animal by 4 weeks 
(Figure 3d left panel). In addition, this population expanded in vivo, and over a highly 
variable time course recipient animals developed an overt LPD indistinguishable from the 
disease in primary animals (Figure 3d right panel). Secondary transplantations performed 
using tumour cells from two recipient animals demonstrated a highly significant reduction in 
disease latency (median 48 vs 132 days, p=0.0002) in keeping with evolution of the B220+/
Mac1Int population to frankly malignant cells (Figure 3e).
Transcriptional, epigenetic and genetic alterations in Crebbp-/- tumours mimic changes in 
human lymphomas
RNA-seq of WT B220+ lymphocytes, and lymphomas from Mx-Crebbp-/- and WT mice 
revealed marked alterations of gene expression (Tables S5-6), with 3546 and 3071 genes 
differentially expressed between Crebbp-/- lymphomas and WT B220+ cells (Figure 4a-b). 
Genes upregulated in frank LPD included the lymphoma oncogenes and self-renewal genes 
Ezh225, Myc, Myb and Gfi-1b26, with downregulated genes including the lymphoma 
tumour suppressors Pten27, Id328 and Irf829, master lymphoid transcription factors Ebf18 
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and Pax530 and class II MHC genes H2-Ab1, H2-Ob and H2-Eb2, previously demonstrated 
to be downregulated in CREBBP mutated lymphomas41. Genotype specific changes 
between Crebbp-/- and WT lymphomas were also evident, including downregulation of Pten 
and upregulation of Ccnd2. Tumours were demonstrated to be clonal by IgH analysis 
(Figure S2). GSEA analysis showed enrichment for the CREBBP mutant signature (Figure 
4c). CREBBP is known to acetylate multiple lysine residues on histones, with H3K27, 
H3K18 and H3K56 acetylation linked to transcription and DNA damage. We detected global 
loss of H3K27Ac in Crebbp-/- LPD compared to WT B220+ B-cells (Figure S3a). We next 
performed genome-scale analysis of these modifications between Crebbp-/- LPD and WT B-
Cells, as well as Crebbp binding in WT B-cells, by ChIP-Seq. Although some loss of 
acetylation was demonstrated for all marks, this was most obvious for H3K27Ac, where 
3360 peaks showed decreased acetylation in Crebbp-/- lymphomas. Furthermore, H3K27Ac 
correlated best with Crebbp binding (Figure 4d-e) and with genes downregulated, where 
1308 of the differential H3K27Ac peaks was linked to a downregulated gene (Figures 4e-f, 
S3b and Tables S7-12). The majority of differential peaks were in enhancers rather than 
promoters, with both super-enhancers and normal enhancers dysregulated (Figure 4g-h). De 
novo motif analysis of differentially bound peaks suggested altered regulation of 
transcriptional networks, including those regulated by Ets, Irf, Ebf and Mef2b transcription 
factors (Figure 4i).
We performed exome-sequencing in 14 Crebbp-/- and all (n=3) WT LPD (Table S13-20). 
Single nucleotide variants and insertion/deletion events included recurrent alterations in the 
Card11 and Gna13 genes and alteration of the Hist1h1d gene in a single case, all genes 
mutated in human lymphoma8, 29 (Figures 5a and S4a). Copy number analysis 
demonstrated recurrent losses and gains, including loss of the Cdkn2a and 2b locus, a 
common alteration in human lymphomas31. We also noted mutations in Ras- and Jak-Stat 
intermediates, pathways known to be activated in human lymphomas7,8,32,33, and could 
demonstrate activation of these pathways in our Crebbp-/- and WT LPD (Figure S4b). 
Analysis of mutation patterns revealed predominantly C > T transitions and C > A 
transversions. Cosine analysis correlated this single signature best with human cancer 
signature 134 (Figures 5b and S4c-d), which reflect the effects of ageing. Taken together, our 
data demonstrate transcriptional, epigenetic and genetic alterations within the Crebbp-/- 
lymphomas that overlap with human disease.
Crebbp modulates DNA damage and protects genomic integrity in lymphoid progenitors
Crebbp has been associated with DNA repair and the cellular response to DNA damage in a 
number of cell types35. This was also suggested by GSEA analysis of differential gene 
expression in Crebbp-/- progenitors (Figure 5c) and we hypothesised that this might 
contribute to tumour evolution within the Crebbp-/- LPD. Therefore, we measured H2AX 
phosphorylation (H2AXγ foci), a surrogate for DNA double stranded breaks, and the 
functional consequences of the DNA damage response (DDR) in IL-7Ra+ progenitors. At 
baseline we found no difference in H2AXγ foci between Mx-Crebbp-/- and WT mice. 
However, when dynamically induced with hydroxyurea (HU) treatment, DNA damage was 
significantly increased in Crebbp-/- mice (Figure 5d-e, p=0.047). However, surprisingly, 
given the degree of DNA damage, there was no expected increase in apoptosis in Crebbp-/- 
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progenitors (Figure 5f). Similarly, in colony forming assays clonogenic potential and 
proliferation were almost fully preserved (Figure 5g). The DDR is orchestrated by p53, 
which in turn requires acetylation by p300 or Crebbp for its full transcriptional output36,37. 
While WT mice demonstrated a brisk acetylation of p53 following DNA damage induction, 
none was evident for mice lacking Crebbp (Figure 5h). In addition, reduced induction of p53 
target genes following DNA damage further demonstrated defective p53 activity (Figure 5i). 
Collectively, these data suggest that loss of Crebbp abrogates optimal cellular response to 
DNA damage, with these subtle changes creating a permissive state for the retention and 
accumulation of subsequent mutations, facilitating transformation.
Evolution at the clonal idiotype, transcriptional and genetic levels in Crebbp-/- lymphomas
The presence and accessibility of the B220+/Mac1Int premalignant stem cell population 
provided us with a unique opportunity to study the evolution of a mature lymphoid 
malignancy, as did comparisons between the premalignant donor cells and their 
lymphomatous progeny harvested from the transplant recipients in Figure 3d. Using a next 
generation sequencing (NGS) method we have developed38, we could demonstrate an early 
reduction in IgH diversity following Crebbp loss (Figure 6a). A further contraction of the 
IgH repertoire was evident upon longitudinal analysis as the LPD/lymphoma developed in 
individual primary mice in vivo, as well as in transplant recipients of premalignant cells 
(Figure 6a-c). Of note, in a small number of cases two IgH rearrangements were evident, and 
sequencing of RNA could demonstrate expression of both rearrangements in keeping with 
the transformation of multiple independent clones (Figure 6b).
Comparing transcriptional changes across WT B cells, B220+/Mac1Int PM stem cells and 
Crebbp-/- lymphoma cells demonstrated significant transcriptional evolution (Figures 6d-e 
and S5a-b). Only 469 and 587 genes were differentially regulated up and down respectively 
at this earlier time point between normal and PM cells (table S21), compared to 3546 and 
3071 genes respectively in the lymphomas (table S22). These already included upregulation 
of Meis3 and multiple Hoxa and b paralogues as wells as downregulation of multiple linker 
histone genes that are mutated in FL, including Hist1h1b and Hist1h1d. In addition, 
differential expression of 205/469 (44%) of upregulated genes and 88/587 (15%) of 
downregulated genes was also evident in the later lymphoma samples (Fig 6e).
Exome sequencing performed across lymphoma evolution in 2 Crebbp-/- LSK HSPC and 8 
premalignant B220+/Mac1Int stem cells, also demonstrated evidence of genetic evolution 
when compared to both Crebbp-/- and WT lymphomas (Figure 6f). This demonstrated a 
sequential increase in the average number of total mutations within these populations 
(p=0.001 between the PM and the LPD), but no difference between Crebbp-/- and WT LPD. 
Exome data was available for the premalignant population transplanted, as well as 6 of the 7 
tumours that developed in recipient mice in Figure 3e. Comparisons of SNV in the PM and 
subsequent tumours demonstrated significant divergent evolution; the transplanted PM cells 
only contained a single SNV (Cbx2), however recipient tumours demonstrated variable 
numbers of SNV (25-47, Table S13), with only 3 SNV common across all cases (Cbx2, 
Celf1 and Ceacam11, Figure 6g).
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Loss of Crebbp in committed lymphoid cells attenuates disease generation and CREBBP 
mutations are present in patient HSPC
The cellular phenotype observed upon Crebbp deletion predominantly reads out in earlier 
lymphoid compartments. To assess whether the tumour suppressor functions of Crebbp were 
necessary at specific stages of lymphoid development and to identify the initial cell of 
transformation in our model, we generated a second mouse strain where Crebbp is deleted 
following lymphoid commitment, using a Cd19-Cre39 (hereafter Cd19-Crebbp-/-). Although 
there was no difference in the efficiency of recombination, we could find no differences in 
the size, composition or function of the HSPC compartment in Cd19-Crebbp -/- mice, in 
marked contrast to early loss of Crebbp (Figures 7a and S6a-c). Similarly, there was no 
difference in basal or induced DNA damage following HU treatment in the early 
compartment (Figure 7b). Only the pro-B population was decreased when later lymphoid 
populations were examined (Figure S6d-e). Although the B220+ Mac1Int population could 
be detected in Cd19-Crebbp-/- mice and occasional mice did develop B-cell LPD, no 
difference in survival was seen between Cd19-Crebbp-/- and WT mice and the number of B-
Cell LPD, and other malignancies, were markedly reduced (Figures 7c-e, S6e and Table 
S23-25). To determine the relevance of these findings for human disease, we screened the 
HSPC compartment of 3 patients with CREBBP-mutated lymphoma (1 DLBCL and 2 FL) 
who lacked BM lymphoma involvement. HSPC were flow sorted and grown as colonies in 
methycellulose (MC) under conditions that only permitted myeloid cell outgrowth and DNA 
harvested (Figure 7f). Sensitive (~1 mutant in 105 wild-type cells) bespoke forward and 
reverse allele-specific PCR assays were developed to screen for sentinel CREBBP mutations 
(Figure S7a-b). Although no evidence for a CREBBP mutation could be found in 2 patients, 
critically, in the remaining patient, the pathogenetic mutation (a 3 base pair deletion leading 
to pS1608delS in the HAT-domain)7 identified in the tumour was also detected in the 
CD19-/CD34+/CD38+ HSPC compartment and confirmed by Sanger sequencing (Figure 7g 
and S7c-d). These data demonstrate that early loss of Crebbp is advantageous for tumour 
formation in our model and that CREBBP mutations may occur in the HSPC compartment 
of patients with lymphoma.
Discussion
CREBBP is mutated or deleted across a wide range of human cancers, identifying it as a 
generic tumour suppressor. In this report, we describe an increased frequency of a number of 
malignancies in Mx-Crebbp-/- mice, and further address the most common phenotype, that 
of mature B-cell malignancies. We mechanistically demonstrate specific loss of H3K27Ac 
that occurs early in lymphoid differentiation and progresses during the evolution of the 
lymphomas. Although, these changes correlate poorly with downregulated genes in early 
pre-malignant progenitors, they and many more enhancers that lose H3K27Ac significantly 
correlate with later downregulated gene expression programmes in overt lymphomas (Figure 
S5b). Of interest, although the acetylation and transcription alterations we report in our 
Crebbp-/- lymphomas mirror recent reports of murine models of follicular lymphomas 
where Crebbp loss or knockdown is combined with Bcl2-overexpression40,41, differences 
are also apparent. In particular, we did not see any enrichment for Bcl6 targets by GSEA or 
de novo motif analysis at Crebbp binding sites or sites with differential H3K27Ac, raising 
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the possibility that loss of Crebbp collaborates with Bcl6 only in the context of Bcl2 
overexpression.
We demonstrate that in the Mx1-Crebbp-/- mice lymphoid progenitor populations 
accumulate, are hyperproliferative and demonstrate altered cellular responses to DNA 
damage upon Crebbp deletion, which we link to the loss of post-translational activation of 
p53. This constellation of alterations cumulatively creates a “perfect storm” for the 
acquisition (hyperproliferation) and retention (inefficient DDR) of mutations and we 
postulate that the “primed” epigenetic state may also favour subsequent transformation by 
these mutations (See models in Figure 8). CREBBP is a global transcriptional coactivator42, 
that interacts with multiple master regulator transcription factors, therefore it is likely that 
aspects of the tumour suppressor phenotype we describe in the context of lymphomagenesis 
also occur across a range of other tumours. However, lymphocytes are highly proliferative 
and undergo additional, significant endogenous physiological DNA damage, through antigen 
receptor rearrangement and somatic hypermutation14. We suggest that our data defining a 
defective DDR provide a plausible explanation for the particularly high rates of CREBBP 
mutations in lymphoid malignancies.
Our model fits with the premise that loss of Crebbp predisposes to the subsequent 
development of mature lymphoid malignancies. This hypothesis would be in keeping with 
the observation that mutation or loss of CREBBP occurs across multiple lymphoma 
phenotypes. This would also fit with our description of Crebbp loss leading to the generation 
of a premalignant stem and progenitor population, with our model being, to our knowledge, 
the only one to demonstrate the existence of such a population for a mature lymphoid 
malignancy. Our study also sheds mechanistic light on the target of initial transformation in 
mature lymphoid malignancies. Early loss of Crebbp in the HSPC compartment resulted in a 
marked cellular phenotype and the development of an aggressive LPD. However, loss in a 
later, fully lymphoid restricted compartment, almost completely abrogated these 
abnormalities significantly attenuating tumour formation. Moreover, we demonstrate that 
CREBBP mutations may occur in rigorously isolated HSPC from patients with CREBBP-
mutated lymphomas. A requirement for early loss of CREBBP function would be in keeping 
with phylogenetic sequencing studies in human follicular lymphoma, which show that 
CREBBP mutation occurs in the earliest inferable lymphoid progenitor11,12, with the 
description of identical EP300 mutations in bone-marrow transplant donor-recipient pairs 
that both went on to develop lymphomas43 and also with the identification that CREBBP 
mutations can rarely occur in HSPC to cause age-related clonal haematopoiesis44. 
Furthermore, mutations of other clonal haematopoiesis genes TET2 and DNMT3A initially 
occurring in the HSPC compartment have been shown to generate predominantly T-cell 
lymphomas in some patients45,46. Evidence from other mouse models would also be in 
keeping with events in earlier progenitor compartments contributing to the development of 
mature B-cell malignancies47–49. Moreover, it is increasingly apparent that for some human 
LPD such as CLL and HCL, driver mutations such as BRAFV600E occur within phenotypic 
HSPC16–18. Taken together, our murine and human data are therefore compatible with 
CREBBP mutations occurring throughout HSPC and later lymphoid ontogeny. Although the 
clinical relevance of this is currently unclear, it merits further investigation and it will be of 
interest to determine whether the first cell type in which the CREBBP mutation occurs as an 
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initiating event has a bearing on the phenotype or clinical outcome of the lymphoma. 
Furthermore, our study models Crebbp loss, and it remains to be seen if altered rather than 
reduced function, perhaps related to specific HAT domain mutants, contribute to lymphoma 
formation. Finally, our findings also provide a mechanistic explanation as to why acquisition 
of the same mutation earlier rather than later in differentiation would be advantageous for 
lymphoma development.
Methods
Mice
C57Bl6 Mx-Crebbp-/- (Crebbp FL/FL; Mx-Cre) conditional knockout mice and the 
induction of Cre-mediated recombination in these animals have been described 
previously21. To induce Cre-mediated recombination, 6- to 10-week-old Mx-Crebbp-/- and 
WT (Crebbp FL/FL; WT) mice were administered 5 doses of poly(I)·poly(C) (pIpC) (300 μg 
per dose; Sigma) by intraperitoneal injection every other day over 10 days. All experiments 
were performed using littermates that were not selected for gender but age-matched in terms 
of date of birth and time of pIpC administration. CD19-Crebbp-/- (Crebbp FL/FL; CD19-
Cre) conditional knockout mice were generated by breeding Crebbp FL/FL mice with 
CD19Cre/+ transgenic mice, both on a C57BL/6 background. Deletion efficiency was 
determined in both cohorts by PCR of genomic DNA extracted from blood or spleen. 
Peripheral blood was collected and counted as described previously21. All mice were 
housed in an SPF animal facility and experiments were conducted under UK Home Office 
regulations. This research has been regulated under the Animals (Scientific Procedures) Act 
1986 Amendment Regulations 2012 following ethical review by the University of 
Cambridge Animal Welfare and Ethical Review Body (AWERB). Power calculations were 
used to generate sample sizes. Randomisation was genetic and the investigators were not 
blinded to group allocations. However, the animal technicians who delivered care and 
decided upon which animals needed to be sacrificed were blinded.
Flow cytometry analysis
Single cell suspensions of bone marrow (BM) cells and splenocytes were prepared as 
described previously50. All staining was performed in Dulbecco’s phosphate-buffered saline 
(DPBS; Gibco Life Technologies) supplemented with 2% fetal bovine serum (FBS; Sigma) 
on ice. Cells were blocked using FcR blocking reagent (Miltenyi Biotech, 1:20) and stained 
with combinations of the antibodies listed in Table S27. Lymphoid progenitors were 
analysed using APC-mouse lineage antibody cocktail (558074, BD Biosciences), FITC anti-
CD127 (IL7-Ra), PE-Cy7 anti-c-Kit and PB anti- Sca1 (Table S27). Dead cells were 
excluded by gating on 7AAD (420403, Biolegend) negative cells. Fluorescence-minus-one 
controls were used to set appropriate gates. Flow cytometry analysis were performed on a 
CyAn ADP flow cytometer (Dako) or an LSR Fortessa cell analyser (BD Biosciences) and 
data were analysed with FlowJo software v 10 (Tree Star).
Histopathology and immunohistochemistry
Tissues were fixed, embedded and sectioned as described previously50. 
Immunohistochemistry was performed using an autoimmunostainer with cover tile 
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technology (Bond-III system, Leica Biosystems). The heat induced antigen retrieval was 
performed using Bond Epitope Retrieval solution 2 (Leca, Biosystem) for 30 minutes. 
Staining was performed using anti-Ki-67 (abcam ab16667, clone SP6, 1:50) followed by 
biotin-SP-conjugated donkey anti-Rabbit IgG (711-066-152; Jackson ImmunoResearch 
Laboratories. Inc) and Vectastain elite ABC kit (Vector labs, Pk-6100). The Bond™ Polymer 
Refine Detection kit (Leica, Biosystems) was used for visualisation.
Isolation of murine cell populations by flow sorting
Lin- CD45+ IL7Ra+ populations were isolated from the BM of Mx-Crebbp-/- and WT mice 
8-10 weeks after poly(I) · poly (C) treatment or from CD19-Crebbp-/- and WT mice 8-10 
weeks after birth. Whole skeletons (except skull and ribs) were pooled and crushed from 3 
animals of each genotype and resuspended in DPBS / 2% FCS. Cells were filtered through a 
70-µm cell strainer (BD Biosciences) and red blood cells (RBC) were lysed using RBC lysis 
buffer (5 PRIME). Lineage-positive cells were depleted prior to sorting using the Easysep 
mouse hematopoietic progenitor cell enrichment kit (19756, Stem Cell Technologies). 
Lineage-depleted cells were stained with V500-streptavidin, CD45.2-FITC and CD127-PE-
Cy7. CD45.2 was used to gate hematopoietic cells and 7AAD was used to exclude dead 
cells. The Lin- c-Kit+ Sca1+ (LSK) and B220+ Mac1int populations from the BM and 
spleens respectively of (pre)-malignant mice were isolated as follows. Lineage-depleted cells 
were prepared from the whole skeleton of individual pre-malignant mice as previously 
described. Cells were stained with V500-streptavidin, CD45.2-FITC, c-Kit-PE-Cy7 and 
Sca1-PB (Table S27). 7AAD was used to exclude dead cells. Total splenocytes were blocked 
and stained with B220-APC and CD11b-FITC. DAPI was used to exclude dead cells. All 
sorting was performed using an Influx cell sorter (BD Biosciences).
Isolation of human cell populations by flow sorting
Bone marrow samples from 3 patients with documented CREBBP mutations were thawed in 
DPBS/ 2% FCS and stained with CD34-APC, CD38-PE-Cy7 and CD19-FITC (Table S27). 
Dead cells were excluded by gating on Zombie Aqua (423101, Biolegend) negative cells. 
Fluorescence-minus-one controls were used to set appropriate gates. CD34+ CD38- CD19- 
and CD34+ CD38+ CD19- cells were sorted using a FACSAria III (BD Biosciences) and 
data analysed with FlowJo software (Tree Star). Cells were cultured in Methocult H4531 
methylcellulose medium (StemCell Technologies) for 7 days and DNA extracted from the 
colonies. Informed consent was obtained from all patients and approved (UK IRAS, REC 
reference: 10/H0704/65, protocol number: 006650QM).
Two allele-specific PCRs were performed. Reaction 1; allele-specific forward primer 5’-
CACTGGGAGTTCTCCTTGCG-3’ and reverse primer 5’-
ACAGGATGCTTCGTCAGACC-3’, reaction 2; forward primer 5’-
GACTAAAGCCCCTCCTCTCC-3’ and allele-specific reverse primer 5’-
GAGCGGCGCAAGGAGAAC-3’. PCR reactions contained 2.5 ng DNA, 400 nM of each 
primer and AmpliTaq Gold® 360 DNA Polymerase. PCR conditions were as follows: a pre-
denaturation of 95 °C for 10 min, 35 cycles of amplification for reaction 1 and 38 cycles for 
reaction 2 (95 °C for 20 s, 66 °C for 30 s and 72 °C for 30 s) and a final extension at 72 °C 
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for 5 min. PCR products were separated on 10 % polyacrylamide gel by electrophoresis and 
confirmed by Sanger sequencing analysis.
Transplantation assays
One million unfractionated (or B220+ Mac1int sorted) splenocytes isolated from individual 
malignant mice were injected intravenously into sub-lethally (550 rads) or lethally irradiated 
(550 rads; 2 doses) C57BL/6 recipients. In other experiments 1 x 106 B220+ Mac1int sorted 
splenocytes isolated from individual pre-malignant mice or 8 x 103 – 2 x 104 LSK cells were 
injected intravenously into lethally irradiated C57BL/6 congenic recipients (CD45.1). When 
recipients were lethally irradiated 2 x 105- 1 x 106 unfractionated CD45.1+ helper BM cells 
were mixed with the donor cells prior to injection. PB chimerism was monitored monthly by 
flow cytometry analysis.
Serial replating assays
Lin-, CD45+, IL7Ra+ cells were plated in MethoCult M3630 methylcellulose medium 
(StemCell technologies) supplemented with 100ng/ml stem cell factor (SCF) and 10ng/ml 
Flt3Ligand (Flt3L; Peprotech) to assess lymphoid potential or Methocult M3434 
methylcellulose medium (StemCell technologies) to assess myeloid potential. Cells were 
plated in duplicate and after 7 days colonies were scored, pooled and identical numbers of 
cells were re-plated under the same conditions.
RNA-Seq
Total RNA was extracted from Lin- CD45+ IL7Ra+ cells isolated from Mx-Crebbp-/- and 
WT mice 8-10 weeks after poly(I) · poly (C) treatment using an RNeasy Plus Micro kit 
(Qiagen). In other experiments RNA was extracted from unfractionated splenocytes of Mx-
Crebbp-/- malignant mice (in which >80% of the cells were B220+) or sorted B220+ cells 
isolated from the splenocytes of WT mice using an RNeasy Plus mini kit (Qiagen). RNA 
quantity and quality was analysed by qubit and bioanalyzer. Ribosomal RNA (rRNA) was 
depleted using a ribozero kit (Illumina) and purified with Qiagen RNA columns. For the WT 
vs malignant LPD comparison approximately 40-95ng of depleted rRNA was used for 
library preparation using a Rapid Directional RNA-seq Kit (5138-08 NEXTflex). Library 
quality was checked and 20nm of each barcoded library was pooled together and sequenced 
at the CRUK Cambridge Institute genomics core (http://www.cruk.cam.ac.uk/core-facilities/
genomics-core).
For the lymphoid progenitor comparison and pre-malignant (B220+ Mac1+) versus WT 
B220+ comparison, RNA libraries were generated from sorted cells using the Ovation 
Mouse RNA-Seq System (0348-32, NuGEN). Ribosomal RNA was then depleted with 
Insert Dependent Adapter Cleavage (InDA-C technology; NuGEN). Library quality was 
checked and then libraries were pooled in equimolar amounts prior to sequencing. All 
experiments were performed in duplicate on biologically independent samples.
RNA-Seq Data Analysis
RNA-Seq reads were aligned to mouse genome (UCSC mm10) using RNA-seq aligner 
STAR (version 2.4.0)51 and the number of uniquely mapping reads were estimated using 
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HTSeq-Count52 and normalized as counts per million. Gene expression read counts were 
analysed to identify differentially expressed genes using DESeq2 (version 1.12.4)53 after 
filtering genes with low read count. Features with adjusted p value <0.1 and absolute l 
logarithmic base 2 fold change >1 were considered as having significant altered expression. 
Differentially expressed genes were analysed for gene set enrichment using GSEA against a 
collection of gene sets and published information54.
ChIP-seq
Lin- CD45+ IL7Ra+ cells (lymphoid progenitors) were isolated from Mx-Crebbp-/- and WT 
mice 8-10 weeks after pIpC treatment. In other experiments unfractionated splenocytes of 
Mx-Crebbp-/- malignant mice (in which >80% of the cells were B220+) or sorted B220+ 
cells isolated from the splenocytes of WT mice were used. Chromatin immunoprecipitation 
was performed with iDeal ChIP-seq kits for Histones and Transcription Factors 
(Diagenode). In brief, 106 or 5x106 cells were crosslinked with 1% formaldehyde (Thermo 
Scientific) for 5 minutes (H3K27ac) or 15 minutes (Crebbp). Fixation was stopped using 
Glycine (Fisher Scientific) and cells were washed twice with ice-cold PBS. Lysis buffer iL1 
(or iL1b) and iL2 were used to prepare the nuclei pellets. Chromatin was sheared in 
Shearing buffer iS1 using the Bioruptor Plus (Diagenode) for 2-2.5 runs of 10 cycles (each 
cycle; 30 seconds “ON” and 45 seconds “OFF”) at high power setting. Immunoprecipitation 
mix was prepared by the addition of ChIP buffer iC1 (or iC1b), BSA, protease inhibitor 
cocktails, pre-washed protein A-coated magnetic beads, antibody (1 µg for anti-H3K27ac 
antibody, ab4729, Abcam; 1 µg for anti-H3K56ac antibody, ab76307, Abcam; 1 µg for anti-
H3K18ac antibody, ab1191, Abcam; 4 µg for anti-Crebbp antibody, sc-369, Santa Cruz) to 
the sheared chromatin and incubated at 4 °C overnight with rotation. Anti-Crebbp antibody 
was pre-incubated in the mix without sheared chromatin at 4 °C for 3-3.5 hours prior to 
overnight incubation. 10% of the sheared chromatins were kept aside as input samples. The 
next day, sequential washes of the chromatin-antibody-beads were performed with ice-cold 
Wash buffer iW1, iW2, iW3 and iW4 and the beads were captured on a magnetic rack. 
Elution buffer iE1 and iE2 were added to the beads and incubated at 65 °C for 4 hours to 
elute and decrosslink the chromatin DNA. Finally, DNA was purified using QIAquick PCR 
Purification Kit (Qiagen) and eluted in 30 µl EB buffer. ChIP-seq library preparation of ChIP 
DNA or input DNA was performed using TruSeq ChIP Sample Prep Kit (Illumina). Library 
DNA was quantified using KAPA Library Quantification Kit (Complete Kit (Universal) for 
Illumina platforms) (Kapa Biosystems) and library average size was determined by Agilent 
DNA 1000 Kit (Agilent Technologies) run on a 2100 Bioanalyser System (Agilent 
Technologies). Libraries were pooled for Single-Read 50bp sequencing on an Illumina 
HiSeq 2500 or 4000 platforms. Experiments were performed in duplicate on biologically 
independent samples apart from Crebbp in WT cells and H3K27Ac in IL7Ra+ cells which 
were performed once.
ChIP-Seq Data Analysis
Sequences were aligned to the mouse reference genome (assembly mm10, Genome 
Reference Consortium GRCm38) using Bowtie software (version 2.1.0)55 allowing a 
maximum mismatch of 2. Duplicates were removed using PICARD tools. The identification 
of ChIP-seq enriched regions (peaks) was performed using MACS (version 2.0.10)56 with a 
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p-value cut-off of 0.005 and the read counts were normalized against input sample. 
Differential binding analysis was performed using the DiffBind package (version 2.0.10)57.
Sample preparation for Exome Sequencing
LSK cells isolated from the BM of pre-malignant mice were expanded in MethoCult M3434 
methylcellulose medium (StemCell technologies). After 7 days colonies were pooled and 
genomic DNA was extracted using a DNeasy blood and tissue kit (Qiagen). DNA was 
extracted from B220+ Mac1int cells sorted from the spleens of pre-malignant mice using the 
same kit. Genomic DNA was isolated from unfractionated BM or spleen cells from 
malignant mice and tail tissue using a Puregene Core kit A (Qiagen).
Sequencing Metric and Somatic Variant Calling Section
Whole exome sequencing was performed using the Agilent whole exome capture kit 
(SureSelect Mouse All Exon, http://www.genomics.agilent.com/article.jsp?
pageId=3102&_requestid=112619). Captured material was indexed and sequenced on the 
Illumina platform at the Wellcome Trust Sanger Institute. Raw pair end sequencing reads 
were aligned with BWA-mem to the GRCm38 mouse reference genome.
Aligned DNA sequence data from paired tumour/normal DNA samples was presented to the 
Cake pipeline, using the somatic variant callers Bambino, Mutect, SAMTools Mpileup, 
Somaticsniper and VarScan2. As described previously58 we used a somatic caller merging 
approach to identify somatic variants selecting only those detected by four or more of these 
algorithms for further analysis. Five (5) of 27 tumours had matched germline DNA, and for 
the remaining tumours we used DNA from mice with the same background. Data was 
further filtered using a pool of germline variants generated by combining the calls from the 5 
available matched normal samples. These calls were further refined by removing germline 
variants identified inhouse by the Wellcome Trust Sanger Institute mouse genome Project.
Mutation Signature Analysis
The mutational catalogue of somatic variants was interpreted using EMu, a probabilistic 
algorithm that infers the number of mutational processes operative in a tumour, and their 
individual signatures59. All somatic point mutations (including silent mutations) were 
mapped to the 96 possible trinucleotide combinations taking into account the opportunity of 
each mutation occurring in the context of each trinucleotide type within the mouse exome. 
We identified one statistically significant mutation signature; xC:G>T:Ax.
We also compared our catalog of mouse mutation signatures against human cancer 
signatures34, after accounting for mutational opportunity. A cosine similarity analysis 
reveals that the the xC:G>T:Ax has strongest correlation with human cancer signature 1.
BCR amplification and sequencing
Genomic DNA was extracted from RBC lysed peripheral blood samples using a KAPA 
Express Extract kit (KAPA Biosystems). DNA was extracted from malignant tissues as 
described previously. PCR amplification of ~10ng of DNA samples was performed with the 
JH reverse primers and the forward primer set pools (group 1 or group 2, 0.25 μM each), 
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using 0.5μl Phusion® High-Fidelity DNA Polymerase (Finnzymes), 1 μl dNTPs (0.25 mM), 
1 μl DTT (0.25 mM), per 50 μl reaction. The following PCR program was used: 3 minutes at 
94°C, 40 cycles of 30 seconds at 94°C, 15 seconds at 60°C and 30 seconds minute at 72 °C, 
with a final extension cycle of 7 minutes at 72 °C on an MJ Thermocycler. Group 1 and 
group 2 primed products were pooled together for each sample. DNA was purified using 
QIAquick PCR Purification Kit (Qiagen) and eluted in 30 µl EB buffer. For each sample 1 
ug DNA was used to prepare the sequencing library using TruSeq DNA PCR-Free Library 
Prep kit (Illumina) (starting from end-repairing onwards). Library DNA was quantified and 
multiplexed for Paired-End 300bp sequencing on Illumina MiSeq platform. MiSeq reads 
were filtered for base quality (median >32) using QUASR60, and paired-end reads merged if 
they contained identical overlapping regions of >65bp, or otherwise discarded. Non-
immunoglobulin sequences were removed and only reads with significant similarity to 
reference IgHV genes in the IMGT database61 by BLAST62 were retained (<1x10-10 E-
value). Primer sequences were trimmed from reads, and sequences retained for analysis only 
if both forward and reverse primer sequences were identified and sequence lengths were 
greater than 240bp for MiSeq. The network generation algorithm and network properties 
were calculated as previously described38: each vertex represents a unique sequence, where 
relative vertex size is proportional to the number of identical reads. Edges join vertices that 
differ by single nucleotide non-indel differences and clusters are collections of related, 
connected vertices. Mutational analysis was performed using IMGT/V-QUEST63.
Cell culture
No cell lines were used in this study. Lin- CD45+ IL7Ra+ cells isolated from Mx-Crebbp-/- 
and WT mice 8-10 weeks after pIpC treatment or from Cd19-Cre and WT mice 8-10 weeks 
after birth were cultured overnight in Iscove’s Modified Dulbecco’s Medium supplemented 
with 5% FBS, 1% penicllin/streptomycin, 0.1 mM non-essential amino acids, 1 mM sodium 
pyruvate, 2 mM glutamine and 50 µM 2-mercaptoethanol (all from Sigma) and 100 ng/ml 
SCF, 20 ng/ml Interleukin-7 (IL-7) and 10 ng/ml Flt3L (peprotech). In some experiments 
cells were cultured overnight with or without a low dose (100 µM) of Hydroxyurea (HU; 
Sigma). For immunoblotting experiments cells were counted the following morning and 
equal cell densities were cultured with 5 µM Trichostatin A (TSA; Sigma) with or without 4 
mM HU for 1 hour. For Q-RT-PCR experiments cells were cultured with 4 mM HU for 4 
hours.
Immunofluoresence
A maximum of 5 x104 cells were adhered to poly-L-lysine (Sigma) coated slides. Soluble 
and cytoskeletal proteins were removed using a modified pre-extraction protocol64. Slides 
were immersed in cytoskeleton buffer (10 mM PIPES (pH 6.8), 100 mM NaCl, 300 mM 
sucrose, 3 mM MgCl2, 1mM EGTA and 0.5% Triton X-100) for 5 min on ice and then 
cytoskeleton stripping buffer (10 mM Tris-HCL (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 1% 
Tween-40 and 0.5% sodium deoxycholate) for 5 min on ice. After washing with PBS on ice 
for 5 min, cells were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature 
(RT), permeabilised in 0.15% Triton X-100 / PBS for 5 min at RT and blocked in 1% Bovine 
Serum Albumin (BSA) / PBS overnight at 4°C. Cells were stained with anti-phospho-
Histone H2AX (Ser139, Millipore, 05-636, clone JBM301, 1:500) for 1 hour at 37°C and 
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then washed with PBS 3 x 5min at RT. Cells were stained with Alexa Fluor 488 goat anti-
mouse (ThermoFisher Scientific, R37120, 1:500) for 1 hour at 37°C, washed with PBS 3 x 
5min at RT and mounted with ProLong Gold mounting medium with DAPI (Invitrogen). A 
minimum of 100 cells were scored using a Zeiss AxioSkop 2 microscope and the number of 
phospho-H2AX foci per cell were recorded from 3 independent experiments. Images were 
acquired using a Zeiss AxioImager Z2 and processed in Zeiss ZEN software.
Apoptosis
A maximum of 5 x104 cells were adhered to poly-L-lysine (Sigma) coated slides and then 
apoptotic cells were detected using an In Situ Cell Death Detection kit, Fluorescein (Roche) 
according to the manufacturer’s instructions. A minimum of 100 cells per condition were 
scored using a Zeiss AxioSkop 2 microscope.
Immunoblotting
Whole cell lysates were prepared from 7 x 105 cells in 2 x SDS-DTT sample buffer. Lysates 
were run on SDS-PAGE gels and transferred to PVDF membranes (Millipore) using 
standard protocols. Membranes were probed with the following primary antibodies at 1:1000 
dilution unless otherwise stated: Acetyl-p53 Lys379 (1:500) (2570; Cell Signalling), total 
p53 (1C12; Cell Signalling), Phospho-p44/42 MAPK (Erk1/2) Thr202/Tyr204 (9101; Cell 
Signalling), p44/42 MAPK (Erk1/2) (9102; Cell Signalling), Phospho-Stat3 (Tyr705) (9131; 
Cell Signaling), Stat3 (79D7) (4904; Cell Signalling), Histone H3 (acetyl K27) (ab4729, 
Abcam), Histone H3 (ab1791, Abcam), Beta Actin (ab8227, Abcam). Membranes were 
probed with secondary antibodies conjugated to horseradish peroxidase (HRP) (GE 
Healthcare; 1:5000) and proteins detected using SuperSignal West Femto kit (Thermo 
Scientific).
q-RT-PCR
Total RNA was isolated using an RNeasy Mini Kit (Qiagen). cDNA was prepared from 0.1 - 
1 µg RNA using the SuperScript III First-Strand Synthesis System (Invitrogen) Q- RT-PCR 
was performed on diluted cDNA (1:10 in water), using Brilliant III Ultra-Fast QPCR Master 
Mix (Agilent) and gene specific primers (Sigma-Aldrich) on an Mx3000p qPCR system 
(Agilent) and standard cycling setup. Primer sequences were retrieved from Primer3 (http://
primer3.ut.ee) and are listed below (F, forward; R, reverse; all 5’-3’): Noxa_F, 
ATAACTGTGGTTCTGGCGCA, and Noxa_R, TCCTTCAAGTCTGCTGGCAC; Puma_F, 
GCGGCGGAGACAAGAAGA, and Puma_R, AGTCCCATGAAGAGATTGTACATGAC; 
Bax_F, TGGAGCTGCAGAGGATGATTG, and Bax_R, AGCTGCCACCCGGAAGA; 
Cdkn1a_F, TTGCACTCTGGTGTCTGAGC, and Cdkn1a_R, 
TGATAGAAATCTGTCAGGCTGGT; Mdm2_F, GGTCCCTGTCCTTTGATCCG, and 
Mdm2_R, CAAGATCCTGATGCGAGGGC; Bcl2_F, GAGCGTCAACAGGGAGATGT, 
and Bcl2_R, GCCGGTTCAGGTACTCAGTC; Gapdh_F, 
TGACGTGCCGCCTGGAGAAA, and Gapdh_R, AGTGTAGCCCAAGATGCCCTTCAG. 
Gene expression levels were determined by 2- ΔΔCT method following normalization to 
Gapdh.
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Code Availability
All codes have been referenced in the appropriate methods section and are also available 
upon request.
Statistics and Reproducibility
Unless otherwise stated, all statistical analyses used unpaired Student’s t-test on raw data. 
All error bars represent the standard error of the mean (SEM). P-values ≤ 0.05 were 
considered statistically significant. All box plots show the median and interquartile range 
and whiskers represent minimum and maximum values. Survival curves were constructed 
using the Kaplan-Meier method and statistical significance was determined using log-rank 
analysis. Hypergeometric tests were performed using phyper function in R stats package. 
The number of independent experiments used to generate statistically significant data are 
defined in the relevant figure legends. The histopatholgy and immunohistochemistry images 
shown in Figure 1d are representative of 7 mice. The flow cytometry images in Figure 1e are 
representative of 7 mice. Immunofluorescence data shown in Figure 5d and 5e were 
generated from 3 independent experiments. The western blot shown in Figure 5h is 
representative of 3 independent experiments. The western blots shown in Figures S3a and 
Figure S4b are representative of 2 independent experiments.
Data Availability
All RNA-Seq and Chip-Seq data have been deposited in the GEO database (GSE923344). 
All data that support the conclusions are available from the authors on reasonable request 
and source data from all graphs are present in Supplementary Table 26.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
The Huntly lab is funded by the ERC (grant 647685 COMAL), KKLF, MRC, Bloodwise, the Welcome Trust (WT) 
and the Cambridge NIHR BRC. We acknowledge the WT/MRC centre grant (097922/Z/11/Z) and support from 
WT strategic award 100140. D.S is a Postdoctoral Fellow of the Mildred-Scheel Organisation, German Cancer Aid. 
We thank Chiara Cossetti, Michal Maj and Reiner Schulte at the CIMR Flow Cytometry Core for their help with 
cell sorting. This research was supported by the Cambridge NIHR BRC Cell Phenotyping Hub. EL is funded by a 
Sir Henry Dale fellowship from the WT/Royal Society.
References
1. Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. 
Blood. 2000; 95:745–755. [PubMed: 10648382] 
2. Roelfsema JH, Peters DJ. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert 
reviews in molecular medicine. 2007; 9:1–16.
3. Kung AL, et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression 
by CBP. Genes & development. 2000; 14:272–277. [PubMed: 10673499] 
4. Cancer Genome Atlas Research, N. Genomic and epigenomic landscapes of adult de novo acute 
myeloid leukemia. N Engl J Med. 2013; 368:2059–2074. DOI: 10.1056/NEJMoa1301689 [PubMed: 
23634996] 
Horton et al. Page 16
Nat Cell Biol. Author manuscript; available in PMC 2018 February 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
5. Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic 
syndromes. Blood. 2013; 122:3616–3627. quiz 3699. DOI: 10.1182/blood-2013-08-518886 
[PubMed: 24030381] 
6. Mullighan CG, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 
471:235–239.
7. Pasqualucci L, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 
471:189–195.
8. Okosun J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns 
driving the initiation and progression of follicular lymphoma. Nat Genet. 2014; 46:176–181. DOI: 
10.1038/ng.2856 [PubMed: 24362818] 
9. Vicente C, et al. Targeted sequencing identifies associations between IL7R-JAK mutations and 
epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica. 2015; 100:1301–
1310. DOI: 10.3324/haematol.2015.130179 [PubMed: 26206799] 
10. da Silva Almeida AC, et al. The mutational landscape of cutaneous T cell lymphoma and Sezary 
syndrome. Nat Genet. 2015; 47:1465–1470. DOI: 10.1038/ng.3442 [PubMed: 26551667] 
11. Green MR, et al. Mutations in early follicular lymphoma progenitors are associated with 
suppressed antigen presentation. Proc Natl Acad Sci U S A. 2015; 112:E1116–1125. DOI: 
10.1073/pnas.1501199112 [PubMed: 25713363] 
12. Green MR, et al. Hierarchy in somatic mutations arising during genomic evolution and progression 
of follicular lymphoma. Blood. 2013; 121:1604–1611. DOI: 10.1182/blood-2012-09-457283 
[PubMed: 23297126] 
13. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare 
cancer stem cells. Science. 2007; 317:337.doi: 10.1126/science.1142596 [PubMed: 17641192] 
14. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005; 5:251–262. 
DOI: 10.1038/nrc1589 [PubMed: 15803153] 
15. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat 
Rev Cancer. 2005; 5:311–321. DOI: 10.1038/nrc1592 [PubMed: 15803157] 
16. Kikushige Y, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of 
human chronic lymphocytic leukemia. Cancer cell. 2011; 20:246–259. DOI: 10.1016/j.ccr.
2011.06.029 [PubMed: 21840488] 
17. Chung SS, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. 
Sci Transl Med. 2014; 6:238ra271.doi: 10.1126/scitranslmed.3008004
18. Damm F, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer 
Discov. 2014; 4:1088–1101. DOI: 10.1158/2159-8290.CD-14-0104 [PubMed: 24920063] 
19. Weigert O, Weinstock DM. The evolving contribution of hematopoietic progenitor cells to 
lymphomagenesis. Blood. 120:2553–2561.
20. Kang-Decker N, et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 
insufficiency. Cancer cell. 2004; 5:177–189. [PubMed: 14998493] 
21. Chan WI, et al. The transcriptional coactivator Cbp regulates self-renewal and differentiation in 
adult hematopoietic stem cells. Mol Cell Biol. 2011; 31:5046–5060. MCB.05830-11 [pii]. DOI: 
10.1128/MCB.05830-11 [PubMed: 22006020] 
22. Xu W, et al. Global transcriptional coactivators CREB-binding protein and p300 are highly 
essential collectively but not individually in peripheral B cells. Blood. 2006; 107:4407–4416. DOI: 
10.1182/blood-2005-08-3263 [PubMed: 16424387] 
23. Wang HC, Perry SS, Sun XH. Id1 attenuates Notch signaling and impairs T-cell commitment by 
elevating Deltex1 expression. Mol Cell Biol. 2009; 29:4640–4652. DOI: 10.1128/MCB.00119-09 
[PubMed: 19564409] 
24. Jiang Y, et al. CREBBP Inactivation Promotes the Development of HDAC3 Dependent 
Lymphomas. Cancer Discov. 2016; doi: 10.1158/2159-8290.CD-16-0975
25. Morin RD, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell 
lymphomas of germinal-center origin. Nat Genet. 2010; 42:181–185. DOI: 10.1038/ng.518 
[PubMed: 20081860] 
Horton et al. Page 17
Nat Cell Biol. Author manuscript; available in PMC 2018 February 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
26. Baron BW, et al. GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene 
to promote the development of lymphomas. Blood Cells Mol Dis. 2014; 52:68–75. DOI: 10.1016/
j.bcmd.2013.07.003 [PubMed: 23910958] 
27. Wang X, Huang H, Young KH. The PTEN tumor suppressor gene and its role in lymphoma 
pathogenesis. Aging (Albany NY). 2015; 7:1032–1049. [PubMed: 26655726] 
28. Schmitz R, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and 
functional genomics. Nature. 2012; 490:116–120. DOI: 10.1038/nature11378 [PubMed: 
22885699] 
29. Li H, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; 
and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 2014; 123:1487–1498. 
DOI: 10.1182/blood-2013-05-500264 [PubMed: 24435047] 
30. Prasad MA, et al. Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their 
synergistic transformation by Pax5 haploinsufficiency. Blood. 2015; 125:4052–4059. DOI: 
10.1182/blood-2014-12-617282 [PubMed: 25838350] 
31. Oricchio E, et al. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests 
a new combination therapy. J Exp Med. 2014; 211:1379–1391. DOI: 10.1084/jem.20132120 
[PubMed: 24913233] 
32. Lohr JG, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma 
(DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012; 109:3879–3884. DOI: 
10.1073/pnas.1121343109 [PubMed: 22343534] 
33. Morin RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. 
Nature. 2011; 476:298–303. DOI: 10.1038/nature10351 [PubMed: 21796119] 
34. Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500:415–
421. DOI: 10.1038/nature12477 [PubMed: 23945592] 
35. Ogiwara H, Kohno T. CBP and p300 histone acetyltransferases contribute to homologous 
recombination by transcriptionally activating the BRCA1 and RAD51 genes. PloS one. 7:e52810.
36. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-
terminal domain. Cell. 1997; 90:595–606. [PubMed: 9288740] 
37. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 
2008; 133:612–626. [PubMed: 18485870] 
38. Bashford-Rogers RJ, et al. Network properties derived from deep sequencing of human B-cell 
receptor repertoires delineate B-cell populations. Genome Res. 2013; 23:1874–1884. DOI: 
10.1101/gr.154815.113 [PubMed: 23742949] 
39. Rickert RC, Roes J, Rajewsky K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. 
Nucleic Acids Res. 1997; 25:1317–1318. [PubMed: 9092650] 
40. Zhang J, et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell 
Lymphoma. Cancer Discov. 2017; 7:322–337. DOI: 10.1158/2159-8290.CD-16-1417 [PubMed: 
28069569] 
41. Garcia-Ramirez I, et al. Crebbp loss cooperates with Bcl2 over-expression to promote lymphoma 
in mice. Blood. 2017; doi: 10.1182/blood-2016-08-733469
42. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes & 
development. 2000; 14:1553–1577. [PubMed: 10887150] 
43. Weigert O, et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after 
hematopoietic cell transplantation. Cancer Discov. 2012; 2:47–55. DOI: 
10.1158/2159-8290.CD-11-0208 [PubMed: 22585168] 
44. Xie M, et al. Age-related mutations associated with clonal hematopoietic expansion and 
malignancies. Nat Med. 2014; 20:1472–1478. DOI: 10.1038/nm.3733 [PubMed: 25326804] 
45. Quivoron C, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse 
and is a recurrent event during human lymphomagenesis. Cancer cell. 2011; 20:25–38. DOI: 
10.1016/j.ccr.2011.06.003 [PubMed: 21723201] 
46. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. 
N Engl J Med. 2012; 366:95–96. DOI: 10.1056/NEJMc1111708 [PubMed: 22216861] 
Horton et al. Page 18
Nat Cell Biol. Author manuscript; available in PMC 2018 February 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
47. Green MR, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of 
mature B-cell lymphoma. Nat Commun. 2014; 5:3904.doi: 10.1038/ncomms4904 [PubMed: 
24887457] 
48. Zhang J, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes 
lymphomagenesis. Nat Med. 2015; 21:1190–1198. DOI: 10.1038/nm.3940 [PubMed: 26366712] 
49. Ortega-Molina A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression 
program that represses B cell lymphoma development. Nat Med. 2015; 21:1199–1208. DOI: 
10.1038/nm.3943 [PubMed: 26366710] 
50. Giotopoulos G, et al. A novel mouse model identifies cooperating mutations and therapeutic targets 
critical for chronic myeloid leukemia progression. J Exp Med. 2015; 212:1551–1569. DOI: 
10.1084/jem.20141661 [PubMed: 26304963] 
51. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29:15–21. DOI: 
10.1093/bioinformatics/bts635 [PubMed: 23104886] 
52. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput 
sequencing data. Bioinformatics. 2015; 31:166–169. DOI: 10.1093/bioinformatics/btu638 
[PubMed: 25260700] 
53. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq 
data with DESeq2. Genome Biol. 2014; 15:550.doi: 10.1186/s13059-014-0550-8 [PubMed: 
25516281] 
54. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting 
genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545–15550. DOI: 
10.1073/pnas.0506580102 [PubMed: 16199517] 
55. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9:357–
359. DOI: 10.1038/nmeth.1923 [PubMed: 22388286] 
56. Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008; 9:R137.doi: 
10.1186/gb-2008-9-9-r137 [PubMed: 18798982] 
57. Stark R, Brown G. DiffBind: differential binding analysis of ChIP-Seq peak data. Bioconductor. 
2011 http://bioconductor.org/packages/release/bioc/html/DiffBind.html. 
58. Thomas RK, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 
2007; 39:347–351. DOI: 10.1038/ng1975 [PubMed: 17293865] 
59. Fischer A, Illingworth CJ, Campbell PJ, Mustonen V. EMu: probabilistic inference of mutational 
processes and their localization in the cancer genome. Genome Biol. 2013; 14:R39.doi: 10.1186/
gb-2013-14-4-r39 [PubMed: 23628380] 
60. Watson SJ, et al. Viral population analysis and minority-variant detection using short read next-
generation sequencing. Philosophical Transactions of the Royal Society B-Biological Sciences. 
2013; 368 doi:Artn 20120205. doi: 10.1098/Rstb.2012.0205
61. Lefranc MP, et al. IMGT, the international ImMunoGeneTics information system. Nucleic acids 
research. 2009; 37:D1006–1012. DOI: 10.1093/nar/gkn838 [PubMed: 18978023] 
62. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. Journal 
of molecular biology. 1990; 215:403–410. DOI: 10.1016/S0022-2836(05)80360-2 [PubMed: 
2231712] 
63. Lefranc MP. IMGT unique numbering for the variable (V), constant (C), and groove (G) domains 
of IG, TR, MH, IgSF, and MhSF. Cold Spring Harb Protoc. 2011; 2011:633–642. DOI: 10.1101/
pdb.ip85 [PubMed: 21632789] 
64. Mirzoeva OK, Petrini JH. DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol 
Cell Biol. 2001; 21:281–288. DOI: 10.1128/MCB.21.1.281-288.2001 [PubMed: 11113202] 
Horton et al. Page 19
Nat Cell Biol. Author manuscript; available in PMC 2018 February 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Loss of Crebbp generates an aggressive mature LPD/Lymphoma.
a. Kaplan-Meier (KM) graph demonstrating significantly reduced survival for Mx-Crebbp-/- 
mice (n = 34 animals) over WT littermates, (n = 23 animals, p < 0.0001) Log-rank (Mantel-
Cox) test. b. Increased incidence of haematological malignancies of Mx-Crebbp-/- mice in 
comparison to WT mice (18 vs 7 cases), that is particularly marked for B-cell LPD (10 vs 3 
cases). c. Mice with B-cell LPD (n = 9 animals) demonstrate a significantly raised WCC 
count in comparison to other Mx-Crebbp-/- mice (n = 14 animals) (** p=0.0034, Mann 
Whitney test). The mean ± standard error of the mean (SEM) is shown. d. Spleen (upper 
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panels H + E) and Lymph node (lower, Ki-67 staining) histology from Mx-Crebbp-/- mice 
with B-cell LPD/Lymphoma. Scale bar: 25µm. e. Immunophenotypic analysis confirming a 
mature B-cell phenotype (CD19+, B220+, sIgM+) with additional aberrant markers (Mac1Int, 
CD5+). f. The disease is transplantable to secondary recipients. Two representative tumours 
2391 and 2634 (7 and 5 recipient animals respectively) are shown.
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Figure 2. Crebbp loss alters stem and progenitor function.
a Representative FACS plots of bone marrow reveal b. a general increase in lin- cells in BM 
(p = 0.0012 by 2-sided t-test with Welch’s correction), and PB (p = 0.01 by 2-sided t-test) 
and in IL-7Ra+ progenitors in BM (p = 0.0065 by 2-sided t-test with Welch’s correction) of 
Mx-Crebbp-/- animals (n = 6 animals per genotype; 3 individual animals per genotype, 
quantified in 2 independent experiments). c. IL-7Ra+ progenitor population from Mx-
Crebbp-/- mice demonstrates an increased clonogenic (left panel) and proliferative (right 
photomicrographs, scale bar 50μM) potential in CFC assays (left, n = 6 animals per 
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genotype; 2 individual animals per genotype, quantified in 3 independent experiments, ** p 
= 0.0024 by 2-sided t-test). All graphs show the median with boxes representing the 
interquartile range and whiskers representing the minimum and maximum values. d. 
Volcano plot of differential gene expression between Mx-Crebbp-/- and WT mice (n = 6 
animals per genotype). P value generated using a negative binomial generalized linear model 
(DEseq2) e. GSEA analysis demonstrates enrichment for a published CREBBP mutant 
lymphoma signature. f. Integration of downregulated differentially bound H3K27Ac peaks 
and downregulated genes demonstrates only minimal overlap. g. Integrated plot showing 
RNA-Seq and H3K27Ac ChIP-Seq at the Dtx1 locus demonstrates that downregulated gene 
expression is accompanied by a statistically significant loss of H3K27ac at an intragenic 
enhancer (boxed) in Crebbp-/- progenitors. All mice were treated with pIpC between 6-10 
weeks after birth (7.7 weeks in Fig a-b, 6.3 weeks in Fig c and 6.9 weeks in Fig d) and 
IL7Ra+ cells isolated from the BM 8-10 weeks (9.6 weeks in Fig a-b, 8.1 weeks in Fig c and 
9 weeks in Fig d) after pIpC administration.
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Figure 3. Development of a pre-malignant stem cell population upon Crebbp loss.
a. An aberrant cell population with similar B220+/Mac1Int surface phenotype to the tumours 
can be found in the PB b. Increase in this aberrant cell population over time following pIpC 
administration (Mx-Crebbp-/-; 67 mice, WT; 64 mice). c. Transplant of this pre-malignant 
stem-cell population into 7 congenic CD45.1 recipient mice generates d. high-level 
engraftment (>25% of peripheral blood cells at 4 weeks, left panel) with sequential in vivo 
amplification of this population seen over time (left panel) ultimately giving rise to elevated 
WBC counts and LPD (right panel). Each separately coloured number (4658, 4659, 4660, 
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4661, 4662, 4663 and 4664) in both panels represents the same individual transplant 
recipient. e. KM graph of survival of the recipient animals in (d) receiving pre-malignant 
B220+/Mac1Int (median survival 132 days) in contrast to LSK cells (n = 7 mice per cell 
population) and secondary recipients of tumour cells from 4661 (n = 5 recipient mice) and 
4663 (n = 3 recipient mice) (median survival 48 days, p = 0.0002, Log-rank (Mantel-Cox) 
test).
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Figure 4. Transcriptional and epigenetic alterations in Crebbp-/- deficient lymphomas.
a. Venn diagrams show overlaps in differentially expressed genes between WT and Mx-
Crebbp-/- lymphomas when compared to WT B220+ cells. Numbers in outer circles are 
inclusive of overlaps, overlapping gene numbers are shown. b. Volcano plot of differential 
gene expression between Mx-Crebbp-/- lymphomas (from n = 2 animals) and WT B220 
cells (from n = 6 animals; B220+ cells from 3 WT animals pooled per sequencing reaction). 
P value generated using a negative binomial generalized linear model (DEseq2). c. GSEA 
analysis of genes differentially expressed between Mx-Crebbp-/- and WT lymphomas 
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demonstrates enrichment of a CREBBP mutant human signature24 and a previously 
published dataset of murine lymphomas. d. H3K27Ac modification measured by specific 
density plots (upper panel) and averaged read counts (lower panel) for genes downregulated 
in Mx-Crebbp-/- lymphomas. e. Significant overlap is seen for Crebbp binding, 
downregulated H3K27Ac peaks (left panel), H3K18Ac peaks (middle panel), H3K56Ac 
peaks (right panel) and genes downregulated in Mx-Crebbp-/- lymphomas compared to WT 
B220+ cells (p values for hypergeometric comparisons are shown). f. Integrated RNA-Seq 
and ChIP-Seq analysis of the Pten locus, a known lymphoma tumour suppressor, in normal 
B220+ B-cells and the B-cell LPD/lymphoma demonstrates decreased H3K27Ac at the 
boxed Crebbp bound peak. g. Downregulated H3K27Ac peaks occur most frequently at 
enhancer regions and h appear to alter the function of genes regulated in WT B220+ cells by 
superenhancers (red) and normal enhancers (black). i. Table demonstrating selected motifs 
enriched in the downregulated H3K27Ac peaks in Mx-Crebbp-/- LPD (ΔH3K27Ac) and 
Crebbp bound peaks in WT B220 cells (Crebbp), as determined by de novo motif analysis.
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Figure 5. Genetic evolution in Crebbp deficient mice is linked to a defective DNA damage 
response.
a. Circos plot showing SNV and copy number analysis for a representative Crebbp-/- 
lymphoma. b. Mutational signature analysis of exome sequencing results for Mx-Crebbp-/- 
tumours (after Alexandrov34), demonstrates an ageing signature. c. GSEA analysis in 
IL-7Ra+ progenitors demonstrates enrichment for DNA repair genes and genes associated 
with DNA damage. d. Bar chart showing the number of double stranded DNA breaks as 
evidenced by H2AXγ foci in IL-7Ra+ progenitors from WT and Mx-Crebbp-/- mice, 
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demonstrating no basal difference, but a marked difference in cells with multiple foci in Mx-
Crebbp-/- progenitors upon the induction of DNA damage with HU. The mean ± SEM is 
shown, n = 3 independent experiments (*p= 0.047 by 2-sided t-test). See Supplementary 
Table 26 for scatter plots of >10 foci. e. Representative image of H2AXγ foci in untreated 
and HU treated Mx-Crebbp-/- cells. Scale bar 10µm. f. Despite the increase in DNA damage 
in Mx-Crebbp-/- mice, no difference in the degree of progenitor apoptosis following HU 
treatment was seen between WT and Mx-Crebbp-/- mice (n = 3 biologically independent 
experiments, 2-sided t-test). g. Preservation of clonogenic capacity in CFC assays for Mx-
Crebbp-/- when compared to WT lymphoid progenitors following HU. The mean ± SEM is 
shown, n = 4 mice per genotype; 2 mice per genotype quantified in 2 independent 
experiments (**p=0.003 by 2-sided t-test). h. Western blot analysis demonstrates that 
following HU, Mx-Crebbp-/- lymphoid progenitors fail to properly acetylate p53 and induce 
an optimal DNA damage response (upper arrow, acetylated (K379) p53, lower arrow, total 
p53). Unprocessed scans of blots are shown in Figure S8. i. Transcriptional activation of 
targets genes suggests a loss of p53 activity. The graph shows data from two independent 
experiments with a line representing the mean.
Horton et al. Page 29
Nat Cell Biol. Author manuscript; available in PMC 2018 February 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 6. Crebbp deficient pre-malignant stem cells demonstrate clonal, transcriptional and 
genetic evolution during lymphomagenesis.
a. Left 2 panels, clonal analysis of IgH DNA rearrangements demonstrates a reduced IgH 
repertoire diversity (number of dots) and an increased maximum clone size (relative size of 
dots, maximum clone size given above each panel) for Mx-Crebbp-/- mice when compared 
to WT littermates. This repertoire narrows further as the pre-malignant (PM) B220+/Mac1Int 
stem cell population increases from 10% to 80% in the PB (2 middle panels) of the same 
animal during disease evolution. b. Similar information in bar chart form. RNA analysis 
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from the last time point demonstrates that both clones are expressed suggesting a cellularly 
biclonal tumour. c. Pie charts to figuratively illustrate the growth of the dominant clone 
donated from the premalignant animal 3975 in the transplant recipients. Colour scheme and 
animal identifiers are as per Figure 3. d. Principle component analysis (PCA) demonstrates 
clear transcriptional differences along the continuum of lymphoma development from WT B 
cells through the PM stage to the Mx-Crebbp-/- lymphoma and between Mx-Crebbp-/- 
tumours and WT lymphomas. e. Venn diagrams document that genes differentially 
expressed in PM cells remain differentially expressed in the same direction in Mx-Crebbp-/- 
lymphomas. Numbers in outer circles are inclusive of overlaps, overlapping numbers are 
shown. f. Scatter plot showing that the total number of SNVs increases along lymphoma 
evolution. Mean ± SEM is shown, LSK n = 2 mice, PM n = 8 mice, Crebbp-/- LPD n = 14 
mice, WT LPD n = 3 mice. P value calculated using 2-sided t-test. g. Mutations in the most 
recurrently altered genes. Results for the premalignant (PM) donor cells from animal 3975 
are aligned beside the tumours that developed from these cells in animals 4659, 4661, 4662, 
4663 and 4644, demonstrating obvious and divergent genetic evolution within the individual 
lymphomas.
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Figure 7. Loss of Crebbp in committed lymphoid cells attenuates disease generation and 
CREBBP mutations occur in HSPC from a lymphoma patient.
a. Analysis of the Lin- and IL7Ra+ compartments in Cd19-Crebbp-/- mice. Box plots show 
the median with interquartile range and whiskers represent the minimum and maximum 
values, n = 6 mice per genotype were quantified. Non-significance confirmed using 2-sided 
t-test. b. Comparison of H2AXγ foci in the IL7Ra+ progenitor populations from Cd19-
Crebbp-/- mice. Data represent the mean ± SEM from n = 3 independent experiments, non-
significance confirmed using 2-sided t-test. See Supplementary Table 26 for scatter plots of 
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>10 foci. c. KM analysis showing that no significant alterations in survival were seen for 
Cd19-Crebbp-/- mice (n = 27 animals) vs WT mice (n = 25 animals). P value calculated 
using Log-rank (Mantel-Cox) test. d. in contrast to that seen in Mx-Crebbp-/- mice. e. B-cell 
disease was very rare in this cohort (Cd19-Crebbp-/- LPD 4 cases, WT LPD 1 case). f. Flow 
sorting strategy to functionally isolate specific HSPC populations from patients with 
CREBBP mutated lymphomas. g. Allele specific PCR demonstrates the presence of the 
same mutation (183 bp band) identified from the tumour (Mut lane) within the CD34+/
CD38+ HSPC population. CFU-colony forming assay, Bl- blank, WT- wild type. h. Model 
of mechanisms and stage specific nature of Crebbp tumour suppression in lymphoid 
malignancies. Following early loss of Crebbp activity in the HSPC compartment, abnormal 
epigenetic regulation, post-translational modifications of substrate proteins and altered 
transcription lead to expansion of lymphoid progenitors, blocked differentiation, increased 
proliferation and clonogenicity within this expanded progenitor pool. In association with an 
alteration of the DNA damage response mediated through suboptimal Crebbp acetylation of 
p53, DNA double strand breaks accumulate and accompanied by a relative decrease in 
apoptosis, lead to the retention of mutations within B-cell progenitors. We illustrate the 
epigenetic priming of specific loci at earlier time points, where H3K27ac ChIP-Seq and 
RNA-Seq at the critical gene X locus read out in terms of downregulation of gene expression 
only at later timepoints during lymphoma evolution. We speculate that the molecular 
aberrations cumulatively acquired interact with this primed epigenetic state and lead to the 
restoration of self-renewal in this abnormal pre-malignant stem cell population and to the 
evolution of Lymphoma.
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